Allergan, Inc.
U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Parsippany
New Jersey
07054
United States
Tel: 1 (862) 261-7000
Website: http://www.allergan.com/
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
YEAR FOUNDED:
1948
LEADERSHIP:
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
1164 articles with Allergan, Inc.
-
Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting
4/27/2021
- New analyses of Phase 3 ARTEMIS studies provide further insights on duration and biodegradation of DURYSTA™ (bimatoprost intracameral implant) - Company will share details of patient-reported outcomes from Phase 3 GEMINI trials for AGN-190584 (pilocarpine 1.25%), a proprietary investigational presbyopia treatment
-
Johnson & Johnson, Endo International, AbbVie’s Allergan unit and Teva Pharmaceutical will head to court this morning in California over claims the companies engaged in deceptive marketing practices that fueled the opioid crisis in America.
-
AbbVie won the NDA on the strength of definitive results in a Phase III ADVANCE trial, where atogepant met all six secondary endpoints at the 30-60 mg dose range, proving statistically significant in heading off migraines in nearly 2500 adult participants who experience them between 4-14 days per...
-
Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia
2/25/2021
Allergan, an AbbVie (NYSE: ABBV) company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia
-
BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition
2/10/2021
Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX® for the treatment of detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.
-
Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference
1/15/2021
Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA)
-
Toronto Cosmetic Surgery Institute One of the First in Canada to Offer Newest Breast Implant by Allergan
1/5/2021
Patients exploring breast implants commonly search for ways to achieve the full look that still feels soft and natural to the touch, without rippling.
-
Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results for Investigational AGN-190584 for the Treatment of Presbyopia
10/28/2020
Allergan, an AbbVie (NYSE: ABBV) company, today announced the Phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint
-
FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity
7/9/2020
Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License Application (sBLA) that supports expanded use of BOTOX® for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy.
-
Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol
6/26/2020
Allerganannounced that the U.S. Food and Drug Administration has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, a novel, investigational DARPin® therapy for patients with neovascular age-related macular degeneration.
-
The U.S. Food and Drug Administration issued a Complete Response Letter, a rejection, of Allergan’s Biologics License Application for Abicipar pegol for neovascular age-related macular degeneration.
-
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
6/22/2020
Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics license application (sBLA) to expand the BOTOX ® prescribing informati
-
Allergan Aesthetics Launches Dedicated Multi-Channel Campaign To Contact Patients Who May Not Be Aware Of The BIOCELL® Recall And To Improve Tracking Information For U.S. Breast Implant Patients
6/1/2020
Connecting with patients to participate in device tracking enables them to be contacted in the event of a safety issue There is no additional safety information being communicated beyond the original July 2019 BIOCELL® recall [01-June-2020] IRVINE, Calif. , June 1, 2020 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is initiating a new di
-
FDA issues warning letters to two breast implant manufacturers as part of ongoing efforts to protect patients
5/14/2020
Today, the U.S. Food and Drug Administration issued warning letters to two breast implant manufacturers for failure to comply with various regulatory requirements.
-
AbbVie Completes Transformative Acquisition of Allergan
5/8/2020
AbbVie, a research-based global biopharmaceutical company, announced that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.
-
The Allergan Foundation Doubles its COVID-19 Response Donations to $4.0 Million
5/7/2020
- Total 2020 Charitable Grants to Date Approach $17 Million - - Lifetime Giving Approaches $112 Million -
-
The U.S. Federal Trade Commission gave the green light to the $63 billion merger of AbbVie and Allergan. That leaves one last hurdle for the two companies, approval from the Irish High Court.
-
AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan
5/5/2020
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with AbbVie's pending acquisition of Allergan.
-
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes to May 8, 2020
4/27/2020
AbbVie Inc. announced the extension of the expiration date of the offers to exchange any and all outstanding notes of certain series issued by Allergan Finance, LLC, Allergan, Inc., Allergan Sales, LLC and Allergan Funding SCS for new notes to be issued by AbbVie and the related consent solicitations being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures governing the Allergan Notes.
-
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes to May 1, 2020
4/20/2020
AbbVie Inc. announced the extension of the expiration date of the offers to exchange any and all outstanding notes of certain series issued by Allergan Finance, LLC, Allergan, Inc., Allergan Sales, LLC and Allergan Funding SCS for new notes to be issued by AbbVie and the related consent solicitations being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures governing the Allergan Notes.